By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Bavarian Nordic Transactions in Connection with Share Buy-Back Program
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Bavarian Nordic Transactions in Connection with Share Buy-Back Program
Bavarian Nordic  Transactions in Connection with Share Buy-Back Program
Health

Bavarian Nordic Transactions in Connection with Share Buy-Back Program

GlobeNews Wire
Last updated: 08/06/2026 2:39 PM
GlobeNews Wire
Published: 08/06/2026
Share
SHARE

COPENHAGEN, Denmark, June 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from June 2, 2026 to July 10, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since initiation of the program, the following transactions have been made by Nordea on behalf of Bavarian Nordic:

  Number of shares Average purchase price, DKK Transaction value, DKK
June 2, 2026  31,294 183.45  5,740,887
June 3, 2026  18,527 180.55  3,344,996
June 4, 2026  348 179.97  62,631
Accumulated under the program 50,169 182.35 9,148,515

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

Following these transactions, Bavarian Nordic holds a total of 2,788,153 treasury shares, corresponding to 3.52% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel. +45 33 26 83 83
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Company Announcement no. 27 / 2026

  • Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
  • Appendix with detailed transaction data
Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute
VALNEVA Declaration of shares and voting rights: January 31, 2026
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
TAGGED:Copenhagen:BAVADK0015998017MyWeb
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
naoo AG Confirms Successful Full-Platform Rollout of Generation V Across iOS and Android
Technology

naoo AG Confirms Successful Full-Platform Rollout of Generation V Across iOS and Android

GlobeNews Wire
GlobeNews Wire
03/04/2026
Hisense named global fastest growing soundbar brand in the past 5 years
$ASTER TGE Day-One Performance Shines: Exclusive Aster DEX Launch Drives $371 Million Trading Volume and nearly 330,000 New Users
Movate Partners with Beacon Mobility to Drive AI-Led Cloud and Cybersecurity Transformation
HTX Unveils Upgraded Brand Digital Avatar “Huobao” and Outlines Strategic Focus on Earn Products
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?